Research progress on clinical efficacy and pharmacological mechanism of salvianolate in treating coronary atherosclerotic heart disease
Coronary atherosclerotic heart disease(CAHD)can be clinically classified as stable angina pectoris(SAP),unstable angina pectoris(UAP),and myocardial infarction(MI),the pathogenesis of which includes endothelial damage,inflammation,oxidative stress,plaque rupture,and thrombosis.Western medicine,percutaneous coronary intervention and coronary artery bypass grafting are effective in the prevention and treatment of CAHD,but the incidence of cardiovascular adverse events is still high.Salvia miltiorrhiza can inhibit inflammation,reduce myocardial ischemic injury,inhibit platelet aggregation and activation,improve MI area,etc.It is one of the most commonly used Chinese medicines in the treatment of chest arthralgia and heartache,and is also a common drug in the treatment of CAHD.This paper reviewed the clinical efficacy and pharmacological mechanism of salvianolate for CAHD,based on the pathogenesis of SAP,UAP and MI,in order to provide reference for clinical practice.
NETL
NSTL
万方数据
